down arrow

Piramal Pharma

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE0DK501011
  • NSEID: PPLPHARMA
  • BSEID: 543635
INR
220.60
12.3 (5.9%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 54.01 lacs

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

212.50222.45

52 Week

132.05307.85
Valuation
Technical
Day's Volume

CASH

54.01 lacs (19.90%) Volume

Shareholding (Dec 2024)

FII

31.68%

Held by 186 FIIs

DII

14.11%

Held by 84 DIIs

Promoter

34.95%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.98 times

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.98 times
  • The company has been able to generate a Return on Equity (avg) of 0.48% signifying low profitability per unit of shareholders funds
2

Flat results in Dec 24

3

Stock is technically in a Mildly Bearish range

4

With ROCE of 4.8, it has a Expensive valuation with a 2.6 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 29,246 Cr (Large Cap)

stock-summary
P/E

526.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.05%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

0.96%

stock-summary
Price to Book

3.49

Revenue and Profits (1 Year):
Net Sales:
2,204 Cr
(Quarterly Results - Dec 2024)
Net Profit:
4 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.05%)
TimePeriod
Price Return
Dividend Return
Total Return
6 Months
-0.63%
0%
-0.63%
1 Year
52.14%
0.07%
52.21%
2 Years
226.14%
0.14%
226.28%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Latest dividend: 0.1 per share ex-dividend date: Jul-12-2024

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
12.67%
EBIT Growth (5y)
505.10%
EBIT to Interest (avg)
0.74
Debt to EBITDA (avg)
5.61
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.62
Tax Ratio
89.47%
Dividend Payout Ratio
81.66%
Pledged Shares
0
Institutional Holding
45.78%
ROCE (avg)
2.16%
ROE (avg)
0.48%
Valuation key factors
Factor
Value
P/E Ratio
526
Industry P/E
33
Price to Book Value
3.49
EV to EBIT
49.67
EV to EBITDA
22.63
EV to Capital Employed
2.60
EV to Sales
3.57
PEG Ratio
1.26
Dividend Yield
0.05%
ROCE (Latest)
4.76%
ROE (Latest)
0.96%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 30 Schemes (11.66%)

FIIs

Held by 186 FIIs (31.68%)

Promoter with highest holding

The Sri Krishna Trust Through Its Trustee Mr. Ajay G Piramal And Dr. (mrs.) Swati A Piramal (26.62%)

Highest Public shareholder

Ca Alchemy Investments (18%)

Individual Investors Holdings

13.29%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -1.67% vs 14.89% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -83.71% vs 125.49% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,204.22",
          "val2": "2,241.75",
          "chgp": "-1.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "337.74",
          "val2": "341.61",
          "chgp": "-1.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "103.31",
          "val2": "107.64",
          "chgp": "-4.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.68",
          "val2": "22.59",
          "chgp": "-83.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "15.32%",
          "val2": "15.24%",
          "chgp": "0.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 14.55% vs 14.31% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is 29.40% vs 36.09% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,192.89",
          "val2": "3,660.23",
          "chgp": "14.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "546.10",
          "val2": "397.96",
          "chgp": "37.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "214.60",
          "val2": "228.39",
          "chgp": "-6.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-66.05",
          "val2": "-93.56",
          "chgp": "29.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "13.02%",
          "val2": "10.87%",
          "chgp": "2.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 13.85% vs 14.25% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 25.26% vs 64.73% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,397.11",
          "val2": "5,618.80",
          "chgp": "13.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "883.84",
          "val2": "666.33",
          "chgp": "32.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "317.91",
          "val2": "334.27",
          "chgp": "-4.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-32.27",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.37",
          "val2": "-83.45",
          "chgp": "25.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "13.82%",
          "val2": "11.86%",
          "chgp": "1.96%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is 15.39% vs 7.97% in Mar 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is 109.56% vs -149.60% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,171.16",
          "val2": "7,081.55",
          "chgp": "15.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,196.26",
          "val2": "628.24",
          "chgp": "90.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "448.49",
          "val2": "344.18",
          "chgp": "30.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-62.79",
          "val2": "-6.96",
          "chgp": "-802.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "17.82",
          "val2": "-186.46",
          "chgp": "109.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "14.64%",
          "val2": "8.87%",
          "chgp": "5.77%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
2,204.22
2,241.75
-1.67%
Operating Profit (PBDIT) excl Other Income
337.74
341.61
-1.13%
Interest
103.31
107.64
-4.02%
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.68
22.59
-83.71%
Operating Profit Margin (Excl OI)
15.32%
15.24%
0.08%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is -1.67% vs 14.89% in Sep 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is -83.71% vs 125.49% in Sep 2024

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
4,192.89
3,660.23
14.55%
Operating Profit (PBDIT) excl Other Income
546.10
397.96
37.22%
Interest
214.60
228.39
-6.04%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-66.05
-93.56
29.40%
Operating Profit Margin (Excl OI)
13.02%
10.87%
2.15%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 14.55% vs 14.31% in Sep 2023

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2024 is 29.40% vs 36.09% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
6,397.11
5,618.80
13.85%
Operating Profit (PBDIT) excl Other Income
883.84
666.33
32.64%
Interest
317.91
334.27
-4.89%
Exceptional Items
0.00
-32.27
100.00%
Consolidate Net Profit
-62.37
-83.45
25.26%
Operating Profit Margin (Excl OI)
13.82%
11.86%
1.96%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 13.85% vs 14.25% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is 25.26% vs 64.73% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
8,171.16
7,081.55
15.39%
Operating Profit (PBDIT) excl Other Income
1,196.26
628.24
90.41%
Interest
448.49
344.18
30.31%
Exceptional Items
-62.79
-6.96
-802.16%
Consolidate Net Profit
17.82
-186.46
109.56%
Operating Profit Margin (Excl OI)
14.64%
8.87%
5.77%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is 15.39% vs 7.97% in Mar 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2024 is 109.56% vs -149.60% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Piramal Pharma Ltd stock-summary
stock-summary
Piramal Pharma Ltd
Large Cap
Pharmaceuticals & Drugs
Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."